Merck expands haematology pipeline with $6.7bn acquisition of Terns Pharmaceuticals

CE2026-03-26T12:41:00

Source: https://www.shutterstock.com/image-photo/kyiv-ukraine-october-16-2021-this-2058895379?trackingId=f97

Deal strengthens Merck’s oncology portfolio with addition of a potential best-in-class oral TKI for chronic myeloid leukaemia.

Merck & Co is acquiring Terns Pharmaceuticals for $6.7 billion, a move that’s set to help build out its haematology pipeline.

The deal includes Terns’ oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI), a potential best-in-class

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member